


**Product Name** : KT185  
**Cat. No.** : PC-20131  
**CAS No.** : 1472640-86-0  
**Molecular Formula** : C<sub>32</sub>H<sub>33</sub>N<sub>5</sub>O<sub>2</sub>  
**Molecular Weight** : 519.65  
**Target** : Phospholipase  
**Solubility** : 10 mM in DMSO



### Biological Activity

KT185 (KT-185) is a potent, selective, irreversible and orally-active  $\alpha/\beta$ -hydrolase domain 6 (**ABHD6**) inhibitor with IC<sub>50</sub> of 0.21 nM.

KT185 inhibits ABHD6 in a 2-arachidonoyl glycerol (2-AG) hydrolysis assay (IC<sub>50</sub>=13.6 nM for the mouse recombinant enzyme expressed in HEK293T cells).

KT185 is selective for ABHD6 over diacylglycerol lipase  $\beta$  (DAGL $\beta$ ) at 1  $\mu$ M, but inhibits lysophospholipase 1 (LYPLA1) and LYPLA2 at 10  $\mu$ M.

KT185 (5-10 mg/kg) inhibits ABHD6 activity in mouse liver and brain in vivo.

KT185 inhibits increases in the frequency of spontaneous inhibitory post-synaptic currents (sIPSCs) induced by nicotine in the rat ventral tegmental area (VTA) but does not reduce nicotine self-administration in rats.

### References

Ku-Lung Hsu, et al. *J Med Chem.* 2013 Nov 14;56(21):8270-9.

Matthew W Buczynski, et al. *Proc Natl Acad Sci U S A.* 2016 Jan 26;113(4):1086-91.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com